Adalbert-Stifter-Weg 2 b
Tel.: +49 1511 15674833
To streamline MRI interpretation in breast cancer patients through an AI-assisted workflow, Quibim is working on a new product that will be of help for lesion characterization, allowing to identify disease subtypes and linking imaging features with patient outcomes. Being able to provide oncologists with a clear answer will allow them to further personalize treatment plans through the combination of imaging with molecular biology information.
Quibim designs pioneering tools that unlock imaging data to improve patient outcomes.
After years of intense research in imaging biomarkers, Quibim (QUantitative Imaging Biomarkers In Medicine) did the commercial launch and internationalization in 2021. Our main purpose is the application of AI techniques to medical images from MRI, CT, PET to unlock new data which can be transformed into actionable predictions for life sciences and providers. The business model is based on a platform marketed through SaaS for hospitals and value-based partnerships in life sciences that help to identify new market needs and create new algorithms.
Having expanded internationally and with a growing team, Quibim is now heading up to bring a new line of products based on predictive imaging biomarker panels.